Related Experiment Videos

Dyslipidemia of chronic renal failure: the nature, mechanisms, and potential consequences

N D Vaziri1

  • 1Division of Nephrology and Hypertension, UCI Medical Center, Orange, CA 92868, USA. ndvaziri@uci.edu

American Journal of Physiology. Renal Physiology
|January 13, 2006
PubMed

Insights

Chronic renal failure causes severe lipid disorders by disrupting high-density lipoprotein (HDL) and triglyceride-rich lipoprotein metabolism, increasing cardiovascular disease risk.

Area of Science:

  • Nephrology
  • Cardiovascular Medicine
  • Lipid Metabolism

Background:

  • Chronic renal failure (CRF) is associated with significant lipid abnormalities.
  • These disorders impact high-density lipoprotein (HDL) and triglyceride-rich lipoprotein (TRL) metabolism.
  • Lipid dysregulation in CRF contributes to increased cardiovascular risk.

Purpose of the Study:

  • To elucidate the mechanisms behind lipid metabolism disturbances in CRF.
  • To understand the roles of specific enzymes and proteins in HDL and TRL dysregulation.
  • To explore the link between these lipid abnormalities and adverse outcomes in CRF patients.

Main Methods:

  • Analysis of lipoprotein metabolism pathways in the context of CRF.
  • Investigation of key enzymes like lecithin-cholesterol acyltransferase (LCAT), cholesteryl ester transfer protein (CETP), hepatic lipase, and lipoprotein lipase.
  • Examination of apolipoprotein (apo) levels, including apoA-I, apoA-II, and apoC-II.

Main Results:

  • CRF impairs HDL maturation and alters its composition, primarily due to reduced LCAT and increased CETP activity.
  • Elevated triglyceride levels and impaired clearance of TRLs and their remnants are observed.
  • Downregulation of lipoprotein lipase, hepatic lipase, and VLDL receptor, alongside ACAT upregulation, contributes to TRL abnormalities.
  • Reduced levels of apoA-I, apoA-II, and apoC-II further compound these metabolic defects.

Conclusions:

  • CRF-induced lipid disorders involve complex dysregulation of HDL and TRL metabolism.
  • These abnormalities, including altered enzyme activities and apolipoprotein levels, are linked to increased arteriosclerotic cardiovascular disease risk.
  • The findings highlight potential targets for managing cardiovascular complications in chronic renal failure.

Related Concept Videos

Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
Nephrotic Syndrome I : Introduction01:24

Nephrotic Syndrome I : Introduction

Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of fluid...
Chronic Kidney Disease I: Introduction01:25

Chronic Kidney Disease I: Introduction

Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Diabetic Nephropathy01:28

Diabetic Nephropathy

Definition Diabetic nephropathy is a chronic kidney complication that results from prolonged hyperglycemia.Prevalence It is the most common cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) worldwide, affecting up to half of individuals with diabetes.Pathophysiology • Sustained hyperglycemia triggers multiple hemodynamic and metabolic changes in the kidney. • Early in the disease, increased renal blood flow and glomerular hyperfiltration occur due to afferent arteriolar...